Navigation Links
Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
Date:12/20/2010

MISSISSAUGA, Ontario, Dec. 20, 2010 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Philip W. Loberg, Valeant's former senior vice president and corporate controller, has been named to the role of interim chief financial officer, effective immediately, replacing Peggy Mulligan, former chief financial officer, who has elected to resign in order to pursue other interests.  The Company has initiated a search to identify a permanent replacement.

"The Board of Directors and I appreciate the contributions Peggy has made during these past few months involving the successful integration activities between Valeant and Biovail and we wish her well in her future endeavors," said J. Michael Pearson, chief executive officer.  "Phil has been an integral part of the Valeant finance department for over 10 years and played key roles in the successful integration of over eighteen acquisitions and several debt financings.  Under Phil's direction, Valeant implemented a turnaround strategy which included strengthening our financial systems and establishing strict internal controls at our various business units.  I am confident that our financial organization will operate seamlessly during this transition process."

Philip W. Loberg joined Valeant in 2000 as treasurer and was appointed chief financial officer of North America in 2006. In 2007, he was appointed to his most recent role of senior vice president, group financial controller, and in that role, Mr. Loberg has been responsible for the upgrading and retooling of the global finance department following restructurings and the disposition of non-performing assets.  In addition, Mr. Loberg simplified and streamlined the SEC compliance and reporting process and was instrumental in the integration of multiple new businesses throughout the global enterprise.  Prior to joining Valeant, Mr. Loberg was the vice president, controller at Calcomp Technology, Inc., a publically traded, majority-owned subsidiary of Lockheed Martin Corporation, and was acting chief financial officer early in his tenure.  Mr. Loberg graduated with a bachelors of science degree from the University of Southern California and completed his CPA exam in 1984.

About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at www.valeant.com.

Forward looking statementsThis press release may contain forward-looking statements, including, but not limited to, statements regarding the successful integration of Valeant and Biovail and the ability of the financial organization to operate seamlessly during this transition process. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.Contact Information:Laurie W. Little949-461-6002laurie.little@valeant.com(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
2. Valeant Announces Pricing of Senior Notes
3. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
4. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
7. Valeant and Biovail Announce Results of Special Meetings of Shareholders
8. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
9. Valeant to Acquire Polish Products
10. Optimer Pharmaceuticals Appoints Gregory Papaz to New Position of Senior Vice President of Commercial Operations
11. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
(Date:9/7/2017)... , Sept. 7, 2017   BioLife Solutions , Inc. ... marketer of proprietary clinical grade cell and tissue hypothermic ... that Mike Rice , President and CEO, will be ... Rodman & Renshaw 19 th Annual Global ... time (12:25 p.m. Pacific time). The conference is being held ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take ... goals to better one’s life through God. “The Trials I Face to Receive God’s ... wrong places, found a love for writing. Green feels that expressing his feelings through ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. ... work and rolled up their sleeves to help with relief efforts. The team picked ... process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
Breaking Medicine News(10 mins):